ClinicalTrials.gg
CompletedNCT01563185Updated Dec 16, 2024Results posted

Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis

A Phase 4 interventional study of 800 mg ibuprofen/26.6 mg famotidine in Juvenile Idiopathic Arthritis, sponsored by Amgen. Completed at 5 sites in United States. Open to participants aged 10 Years to 16 Years. Per ClinicalTrials.gov, last updated 2024-12-16.

Sponsored by Amgen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
10 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 109 studies in Arthritis, Juvenile with a site in United States — 20 open to participants now, 23 under way, 5 of them phase 3. Arthritis, Juvenile · United States.

Enrollment
68th of 83
12 · median 55
Started
2012
with 7 others
Phase 4
7 of 109
none open now
Registered
49th of 109
by date

Among the 109 studies in Arthritis, Juvenile with a site in United States, this one is the 68th largest by enrollment of the 83 interventional ones that give a count, is one of 8 that started in 2012, is one of 7 in phase 4, and was the 49th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

20 of the 109 studies in Arthritis, Juvenile with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 10 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Arthritis, Juvenile with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this Phase 4, multi-center, open-label study is to evaluate the safety and tolerability of DUEXIS in Juvenile Idiopathic Arthritis (JIA) patients aged 10 years to 16 years, 11 months, treated up to 24 weeks.

The secondary objectives are to evaluate the PK characteristics of DUEXIS in JIA patients and to evaluate the signs and symptoms of JIA in patients aged 10 years to 16 years, 11 months receiving DUEXIS for up to 24 weeks.

Read the detailed description

Approximately 30 JIA patients who meet all eligibility criteria and who are expected to require daily administration of an NSAID for up to 24 weeks will be enrolled. A subset of approximately 6 patients will participate in a single dose PK study at Day 0 with an abbreviated PK profile performed at Week 4 if possible. Multiple dose PK sampling will occur in all enrolled patients.

Study with completed results acquired from Horizon in 2024

03

Conditions studied

  • Juvenile Idiopathic Arthritis

Browse trials for

Keywords

  • JIA
  • ibuprofen
  • famotidine
  • pediatrics
  • for > 1 month
04

Who can participate

Ages eligible
10 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient and guardian are willing to consent to undergo up to 24 weeks of treatment with DUEXIS (ibuprofen 800 mg/famotidine 26.6 mg) oral tablet three times daily.
  2. Patient is male or female, aged 10 years to 16 years, 11 months.
  3. Patient is diagnosed with JIA for > 1 month including oligoarthritis, polyarthritis rheumatoid factor (RF) +, polyarthritis RF-, psoriatic arthritis, enthesitis-related arthritis, or undifferentiated and systemic arthritis without systemic features in the past 6 months.
  4. Patient must have currently active articular disease as defined by > 1 active joint (i.e., presence of swelling, or if no swelling is present, limitation of motion [LOM] accompanied by pain, tenderness, or both).
  5. Based upon investigator judgment, given current treatment patient is receiving and level of disease activity, it is determined appropriate for the patient to undergo up to 24 weeks of treatment with DUEXIS (ibuprofen 800 mg/famotidine 26.6 mg) oral tablet three times daily. The investigator will use his/her clinical judgment in determining the duration of treatment for the patient based on the standard of care up to 24 weeks of treatment.
  6. Weight > 48 kg and (BMI) > 5th percentile using the Centers for Disease Control (CDC) BMI percentile calculator for child and teen at the screening visit.
  7. Patient is able to swallow a DUEXIS tablet whole.
  8. For the single dose pharmacokinetic (PK) subset, patients and guardians must be willing to participate in the serial blood sample collections at Day 0 and Week 4.
  9. Female patients of and male patients must agree to use medically acceptable methods of , including abstinence, throughout the entire study period.
  10. Patient is willing and able to comply with the prescribed treatment protocol and evaluations.

Exclusion criteria

Exclusion Criteria:

  1. Patient has a history of or experienced any of the following:

    • NSAID-associated and/or primary peptic ulcer disease-associated serious gastrointestinal complications such as perforation of ulcers, gastric outlet obstruction due to ulcers, and/or acute gastrointestinal bleeding
    • NSAID-induced asthma exacerbation, acute renal failure, interstitial nephritis, and/or hepatitis
    • Malignant disease of the gastrointestinal tract
    • Erosive esophagitis
    • Coronary artery bypass graft (CABG) surgery within the 14 days prior to study Day 0
    • Uncontrolled diabetes mellitus as evidenced by > 7%
    • Known history of (HIV), , and/or .
  2. Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological, or cerebral disease.
  3. JIA disease is severe as defined by either physician's or parent's global assessments > 90 on a 100 point scale.
  4. Systemic JIA with any of the following manifestations within the last 6 months prior to enrollment: intermittent fever due to JIA, rheumatoid rash, hepatosplenomegaly, pleuritis, pericarditis, or macrophage activation syndrome.
  5. Active uveitis.
  6. Presence of any other rheumatic disease or major chronic infectious, inflammatory, immunologic disease (e.g., inflammatory bowel disease, hypogammaglobulinemia, or systemic lupus erythematosus, etc.).
  7. Presence at screening or history of any disease other than JIA that requires the use of chronic systemic .
  8. History of drug or alcohol abuse.
  9. Presence at screening of any of the following laboratory values:

    • \< 9.0 g/dL
    • White blood cells \< 2000/mm\^3 (2 x 109/L)
    • \< 150,000/mm\^3 (150 x 109/L)
    • Serum creatinine > 1.5 times
    • Serum or AST > 2.0 times upper limit of normal
    • H. pylori positive
    • Any other lab value that in the opinion of the investigator might place the patient at unacceptable risk for participation in this study.
  10. Methotrexate > 20 mg/M\^2/week or > 40 mg/week.
  11. Patient currently is participating in an drug study, or patient participated in an investigational drug study within the 30 days (or \< 5 terminal half-lives of elimination) prior to study entry.
  12. Females who are pregnant or breast feeding.
  13. Female patient has a positive serum pregnancy test at Screening and/or a positive urine pregnancy test at Study Day 0.
  14. Patient has a concomitant disease or condition that, in the opinion of the Investigator, could interfere with the conduct of the study or could put the patient at unacceptable risk
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    DUEXIS

    800 mg ibuprofen/26.6 mg famotidine

    Drug: 800 mg ibuprofen/26.6 mg famotidine

Interventions

  • Drug800 mg ibuprofen/26.6 mg famotidine

    Drug pages: Ibuprofen · Famotidine

    Oral tablet taken three time per day

    Also known as: DUEXIS

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)

    Safety assessments included AE monitoring, concomitant medication review, physical examinations (including vital signs and weight), and clinical laboratory assessments, including pregnancy testing for female patients. The outcome measure data table below describes the TEAEs experienced by patients.

    Time frame: Day 0 through Week 26/ET (adverse event data was collected at every visit, including telephone visits)

Secondary outcomes

  1. Childhood Health Questionnaire Parent Form 50 (CHQ-PF50) Scores

    To assess patient quality of life while on study medication, the CHQ was administered to the patients' parent or guardian on Day 0 and at the Week 24/ET visit. The raw scale scores were transformed into scores on a 0 to 100 scale, 100 indicating best health and 0 indicating worst health. The algorithm is: Transformed Score = ((Actual Raw Score - Lowest Possible Raw Score)/(Possible Raw Score Range)) x100. The actual raw score is the mean of the item responses in a scale (sum of item responses/number of completed items). The possible raw score range is the highest possible raw score minus the lowest possible raw score. The outcome measure data table shows the average change in the CHQ concepts from Baseline to the week 24 visit. The average change in the CHQ concepts is on a -100 to 100 scale, -100 representing a negative change in health and 100 indicating a positive change in health.

    Time frame: Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).

  2. American College of Rheumatology (ACR) Pediatric Core Measures: Physician's Global Assessment of Disease Activity and Parent's Assessment of Overall Well-being

    The following 2 ACR pediatric Core Measures of JIA activity and the parent's assessment of discomfort were quantitatively assessed at baseline and each study visit: the physician's global assessment of disease activity and the parent's global assessment of overall well-being. These ACR values represent the average change in the physician's global assessment of disease activity and the parent's global assessment of overall well-being from the baseline visit to the week 24/ET visit. The ACR pediatric core measure: Physician's global assessment of disease activity and parent's assessment of overall well being was measured on a scale of 0-100 mm (0 = very good, 100=very poor).

    Time frame: Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).

  3. American College of Rheumatology (ACR) Pediatric Core Measures: CHAQ - Disability Index

    The following ACR pediatric Core Measure of JIA activity and the parent's assessment of discomfort were quantitatively assessed at baseline and each study visit: CHAQ - Disability Index. This ACR measurement represents the average change in the Childhood Health Assessment Questionnaire (CHAQ) - Disability Index from the baseline visit to the week 24/ET visit. The CHAQ disability index is measured on a scale of 0-3 (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do).

    Time frame: Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).

  4. ACR Pediatric Components by Time Point: Number of Joints With Active Arthritis and the Number of Joints With Limited Range of Motion Number of Joints With Active Arthritis

    The following 2 ACR pediatric Core Measures of JIA activity and the parent's assessment of discomfort were quantitatively assessed at baseline and each study visit: number of joints with active arthritis and the number of joints with limited range of motion. These ACR values represent the average change in number of joints with active arthritis and the number of joints with limited range of motion from the baseline visit to the week 24/ET visit. The joints that were assessed include the right and left temporomandibular, sternoclavicular, arcomiclavicular, shoulder, elbow, wrist, MCP - 1. MCP - 2, MCP - 3, MCP - 4, MCP - 5, PIP - 1, PIP - 2, PIP - 3, PIP - 4, PIP - 5, DIP - 1, DIP - 2, DIP - 3, DIP - 4, and DIP - 5.

    Time frame: Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).

  5. American College of Rheumatology (ACR) Pediatric Core Measures: Serum C Reactive Protein (CRP) Concentration

    The following ACR pediatric Core Measure of JIA activity and the parent's assessment of discomfort were quantitatively assessed at baseline and each study visit: CRP Concentration. This ACR value represents the average change in Serum C Reactive Protein (CRP) Concentration from the baseline visit to the week 24/ET visit. The normal range referenced was 0 mg/L - 4.99 mg/L.

    Time frame: Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).

  6. Single Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Time of Maximum Observed Concentration (Tmax)

    Tmax was estimated for ibuprofen and famotidine.The PK parameters for ibuprofen and famotidine represent average Tmax values following a single oral dose of DUEXIS. Samples were collected pre-dose and at 0.5, 1, 2, 4, and 8 to 10 hours following study drug administration.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 8 hours post-dose

  7. Single Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Maximum Observed Concentration (Cmax)

    Cmax was estimated for ibuprofen and famotidine. The PK parameters for ibuprofen and famotidine represent average Cmax values following a single oral dose of DUEXIS. Samples were collected pre-dose and at 0.5, 1, 2, 4, and 8 to 10 hours following study drug administration.

    Time frame: Pre-dose, and 0.5, 1, 2, 4, 8 hours post-dose

  8. Single Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Area Under the Concentration-time Curve From the Time of Dosing to the Last Measurable Concentration (AUC(0-t))

    AUC(0-t) was estimated for ibuprofen and famotidine. The PK parameters for ibuprofen and famotidine represent average AUC values following a single oral dose of DUEXIS. Samples were collected pre-dose and at 0.5, 1, 2, 4, and 8 to 10 hours following study drug administration.

    Time frame: Pre-dose, and 0.5, 1, 2, 4, 8 hours post-dose

  9. Multiple Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Individual Oral Clearance (CL/F)

    CL/F was estimated in ibuprofen and famotidine.

    Time frame: Pre-dose and 0.5, 1, 2, 4, and 8 hours post-dose in the single dose group; sparse samples at random times in the multiple dose group

  10. Multiple Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Volume Distribution (V/F)

    V/F were estimated in ibuprofen and famotidine.

    Time frame: Pre-dose and 0.5, 1, 2, 4, and 8 hours post-dose in the single dose group; sparse samples at random times in the multiple dose group

07

Results

Posted Dec 23, 2015

Participant flow

Participant flow — Overall Study
MilestoneDUEXIS
Started12
Completed10
Not completed2
Withdrew: Withdrawal by subject1
Withdrew: Non-compliance with study drug1

Outcome measures

PrimaryNumber of Participants Reporting Treatment Emergent Adverse Events (TEAEs)

Safety assessments included AE monitoring, concomitant medication review, physical examinations (including vital signs and weight), and clinical laboratory assessments, including pregnancy testing for female patients. The outcome measure data table below describes the TEAEs experienced by patients.

Time frame:
Day 0 through Week 26/ET (adverse event data was collected at every visit, including telephone visits)
Reported as:
Number · participants
Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)
participantsDUEXIS
Any patient with at least 1 TEAE12
Any patient with at least 1 mild TEAE7
At least 1 moderate TEAE5
At least 1 severe TEAE0
A possibly related TEAE2
SAE0
A TEAE leading to study drug discontinuation0
A TEAE leading to death0
TEAE: Gastrointestinal Disorders4
TEAE: General disorders2
TEAE: Infections and infestations7
TEAE: Injury, poisoning & procedural complications2
TEAE: Muscoskeletal & connective tissue disorders2
TEAE: Nervous system disorders1
TEAE:Respiratory, thoracic & mediastinal disorders3
TEAE: Skin and subcutaneous tissue disorders2
SecondaryChildhood Health Questionnaire Parent Form 50 (CHQ-PF50) Scores

To assess patient quality of life while on study medication, the CHQ was administered to the patients' parent or guardian on Day 0 and at the Week 24/ET visit. The raw scale scores were transformed into scores on a 0 to 100 scale, 100 indicating best health and 0 indicating worst health. The algorithm is: Transformed Score = ((Actual Raw Score - Lowest Possible Raw Score)/(Possible Raw Score Range)) x100. The actual raw score is the mean of the item responses in a scale (sum of item responses/number of completed items). The possible raw score range is the highest possible raw score minus the lowest possible raw score. The outcome measure data table shows the average change in the CHQ concepts from Baseline to the week 24 visit. The average change in the CHQ concepts is on a -100 to 100 scale, -100 representing a negative change in health and 100 indicating a positive change in health.

Time frame:
Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).
Reported as:
Mean · units on a scale
Childhood Health Questionnaire Parent Form 50 (CHQ-PF50) Scores
units on a scaleDUEXIS
Global Health2.5 ± 21.16
Physical Functioning19.0 ± 36.29
Role/Social Limitations: Emotional/Behavioral14.8 ± 35.86
Role/Social Limitations: Physical20.8 ± 32.68
Bodily Pain/Discomfort15.8 ± 27.12
Behavior8.4 ± 13.29
Global Behavior Item6.7 ± 10.30
Mental Health3.3 ± 9.37
Self Esteem5.3 ± 12.47
General Health Perceptions1.9 ± 14.40
Change in Health14.6 ± 39.11
Parental Impact: Emotional20.4 ± 24.51
Parental Impact:Time22.2 ± 30.92
Family Activities14.3 ± 26.80
Family Cohesion4.6 ± 8.65
SecondaryAmerican College of Rheumatology (ACR) Pediatric Core Measures: Physician's Global Assessment of Disease Activity and Parent's Assessment of Overall Well-being

The following 2 ACR pediatric Core Measures of JIA activity and the parent's assessment of discomfort were quantitatively assessed at baseline and each study visit: the physician's global assessment of disease activity and the parent's global assessment of overall well-being. These ACR values represent the average change in the physician's global assessment of disease activity and the parent's global assessment of overall well-being from the baseline visit to the week 24/ET visit. The ACR pediatric core measure: Physician's global assessment of disease activity and parent's assessment of overall well being was measured on a scale of 0-100 mm (0 = very good, 100=very poor).

Time frame:
Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).
Reported as:
Mean · units on a scale
American College of Rheumatology (ACR) Pediatric Core Measures: Physician's Global Assessment of Disease Activity and Parent's Assessment of Overall Well-being
units on a scaleDUEXIS
Physician's Global Assessment of Disease Activity-9.1 ± 28.34
Parent's Global Assessment of Overall Well-Being-8.0 ± 34.07
SecondaryAmerican College of Rheumatology (ACR) Pediatric Core Measures: CHAQ - Disability Index

The following ACR pediatric Core Measure of JIA activity and the parent's assessment of discomfort were quantitatively assessed at baseline and each study visit: CHAQ - Disability Index. This ACR measurement represents the average change in the Childhood Health Assessment Questionnaire (CHAQ) - Disability Index from the baseline visit to the week 24/ET visit. The CHAQ disability index is measured on a scale of 0-3 (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do).

Time frame:
Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).
Reported as:
Mean · units on a scale
American College of Rheumatology (ACR) Pediatric Core Measures: CHAQ - Disability Index
units on a scaleDUEXIS
American College of Rheumatology (ACR) Pediatric Core Measures: CHAQ - Disability Index-0.146 ± 0.3235
SecondaryACR Pediatric Components by Time Point: Number of Joints With Active Arthritis and the Number of Joints With Limited Range of Motion Number of Joints With Active Arthritis

The following 2 ACR pediatric Core Measures of JIA activity and the parent's assessment of discomfort were quantitatively assessed at baseline and each study visit: number of joints with active arthritis and the number of joints with limited range of motion. These ACR values represent the average change in number of joints with active arthritis and the number of joints with limited range of motion from the baseline visit to the week 24/ET visit. The joints that were assessed include the right and left temporomandibular, sternoclavicular, arcomiclavicular, shoulder, elbow, wrist, MCP - 1. MCP - 2, MCP - 3, MCP - 4, MCP - 5, PIP - 1, PIP - 2, PIP - 3, PIP - 4, PIP - 5, DIP - 1, DIP - 2, DIP - 3, DIP - 4, and DIP - 5.

Time frame:
Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).
Reported as:
Mean · Number of joints
ACR Pediatric Components by Time Point: Number of Joints With Active Arthritis and the Number of Joints With Limited Range of Motion Number of Joints With Active Arthritis
Number of jointsDUEXIS
Number of joints with active arthritis-4.3 ± 6.97
Number of joints with limited range of motion-1.7 ± 5.43
SecondaryAmerican College of Rheumatology (ACR) Pediatric Core Measures: Serum C Reactive Protein (CRP) Concentration

The following ACR pediatric Core Measure of JIA activity and the parent's assessment of discomfort were quantitatively assessed at baseline and each study visit: CRP Concentration. This ACR value represents the average change in Serum C Reactive Protein (CRP) Concentration from the baseline visit to the week 24/ET visit. The normal range referenced was 0 mg/L - 4.99 mg/L.

Time frame:
Baseline to Endpoint (Endpoint is the last post-baseline value obtained, as two subjects did not complete the study up until week 24).
Reported as:
Mean · mg/L
American College of Rheumatology (ACR) Pediatric Core Measures: Serum C Reactive Protein (CRP) Concentration
mg/LDUEXIS
American College of Rheumatology (ACR) Pediatric Core Measures: Serum C Reactive Protein (CRP) Concentration1.019 ± 3.9742
SecondarySingle Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Time of Maximum Observed Concentration (Tmax)

Tmax was estimated for ibuprofen and famotidine.The PK parameters for ibuprofen and famotidine represent average Tmax values following a single oral dose of DUEXIS. Samples were collected pre-dose and at 0.5, 1, 2, 4, and 8 to 10 hours following study drug administration.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 8 hours post-dose
Reported as:
Mean · hours
Single Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Time of Maximum Observed Concentration (Tmax)
hoursDUEXIS
Tmax: Ibuprofen1.75 ± 0.66
Tmax: Famotidine2.1 ± 0.14
SecondarySingle Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Maximum Observed Concentration (Cmax)

Cmax was estimated for ibuprofen and famotidine. The PK parameters for ibuprofen and famotidine represent average Cmax values following a single oral dose of DUEXIS. Samples were collected pre-dose and at 0.5, 1, 2, 4, and 8 to 10 hours following study drug administration.

Time frame:
Pre-dose, and 0.5, 1, 2, 4, 8 hours post-dose
Reported as:
Mean · ug/mL
Single Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Maximum Observed Concentration (Cmax)
ug/mLDUEXIS
Cmax: Ibuprofen49.8 ± 13.7
Cmax: Famotidine55.0 ± 11.9
SecondarySingle Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Area Under the Concentration-time Curve From the Time of Dosing to the Last Measurable Concentration (AUC(0-t))

AUC(0-t) was estimated for ibuprofen and famotidine. The PK parameters for ibuprofen and famotidine represent average AUC values following a single oral dose of DUEXIS. Samples were collected pre-dose and at 0.5, 1, 2, 4, and 8 to 10 hours following study drug administration.

Time frame:
Pre-dose, and 0.5, 1, 2, 4, 8 hours post-dose
Reported as:
Mean · ug*h/mL
Single Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Area Under the Concentration-time Curve From the Time of Dosing to the Last Measurable Concentration (AUC(0-t))
ug*h/mLDUEXIS
AUC(0-t): Ibuprofen196.5 ± 27.4
AUC(0-t): Famotidine267.6 ± 27.1
SecondaryMultiple Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Individual Oral Clearance (CL/F)

CL/F was estimated in ibuprofen and famotidine.

Time frame:
Pre-dose and 0.5, 1, 2, 4, and 8 hours post-dose in the single dose group; sparse samples at random times in the multiple dose group
Reported as:
Mean · L/h/70 kg
Multiple Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Individual Oral Clearance (CL/F)
L/h/70 kgDUEXIS
CL/F: Ibuprofen2.8 ± 0.6
CL/F: Famotidine61.5 ± 15.9
SecondaryMultiple Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Volume Distribution (V/F)

V/F were estimated in ibuprofen and famotidine.

Time frame:
Pre-dose and 0.5, 1, 2, 4, and 8 hours post-dose in the single dose group; sparse samples at random times in the multiple dose group
Reported as:
Mean · L/70 kg
Multiple Dose Pharmacokinetic Characteristics of DUEXIS in JIA Patients: Volume Distribution (V/F)
L/70 kgDUEXIS
V/F: Ibuprofen16.7 ± 4.6
V/F: Famotidine564.4 ± 154.6

Adverse events

Collected over Adverse events were collected from the Day 0 visit up until the Follow-up visit (Week 26). Adverse events were collected at the following time points: Day 0, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, and Week 26.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DUEXIS—0/12 (0%)12/12 (100%)
Most frequent other events
Showing 10 of 27
Most frequent other events
EventDUEXIS
DiarrhoeaGastrointestinal disorders2/12
Ingrowing nailSkin and subcutaneous tissue disorders2/12
Abdominal pain upperGastrointestinal disorders1/12
ConstipationGastrointestinal disorders1/12
Gastrooesophageal reflux diseaseGastrointestinal disorders1/12
HaematocheziaGastrointestinal disorders1/12
NauseaGastrointestinal disorders1/12
Tooth impactedGastrointestinal disorders1/12
FatigueGeneral disorders1/12
Gait disturbanceGeneral disorders1/12

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)DUEXIS
<=18 years12
Between 18 and 65 years0
>=65 years0
Age, Continuous
Age, Continuous(years)DUEXIS
Mean13.8 ± 1.71
Sex: Female, Male
Sex: Female, Male(Participants)DUEXIS
Female5
Male7
Region of Enrollment
Region of Enrollment(participants)DUEXIS
United States12
08

Study locations

5 sites
  • Children's Hospital
    New Orleans, Louisiana 70118, United States
  • Floating Hospital for Children @ Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • UMASS Memorial Children's Medical Center
    Worcester, Massachusetts 01655, United States
  • Altoona Center for Clinical Research Altoona Arthritis
    Duncansville, Pennsylvania 16635, United States
  • Dell Children's Medical Center of Central Texas
    Austin, Texas 78723, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2012
First posted
Mar 26, 2012
Start
Apr 2012
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Results first posted
Dec 23, 2015
Last update
Dec 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01563185
Lead sponsor
Amgen
Collaborators
Pediatric Rheumatology Collaborative Study Group
Responsible party
Sponsor
First posted
Mar 26, 2012
Start date
Apr 2012
Primary completion
Mar 2015
Completion
Mar 2015
Results posted
Dec 23, 2015
Last update
Dec 16, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibuprofen · Famotidine

Start the discussion